Kura Oncology's Darlifarnib Shows 44% ORR, 94% DCR in Difficult-to-Treat Kidney Cancer Patients
Summary
Kura Oncology reported robust preliminary data from a subset analysis of its darlifarnib (KO-2806) in combination with cabozantinib for clear cell renal cell carcinoma (ccRCC) patients previously treated with cabozantinib. The data showed a 44% objective response rate (ORR) and a 94% disease control rate (DCR) in this heavily pretreated population, with tumor shrinkage observed in 75% of patients. These findings are highly significant as they suggest darlifarnib can overcome resistance to prior cabozantinib therapy and provide meaningful clinical benefit in a refractory setting where treatment options are limited. This positive clinical update pertains to a key pipeline asset, distinct from recent equity plan filings, and demonstrates progress in the company's oncology pipeline as highlighted in its last 10-K. Strong efficacy data for a drug in a difficult-to-treat cancer population can substantially increase the drug's commercial potential and impact the company's valuation. Investors will be watching for further development of darlifarnib, including its advancement into Phase 1b dose expansion, and future regulatory pathways.
At the time of this announcement, KURA was trading at $9.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $789.7M. The 52-week trading range was $5.45 to $12.49. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.